Featured Innovator :: Amorphical
Inspired by blue crabs, Yossi Ben founded Amorphical in 2004, developing and manufacturing a proprietary synthetic form of calcium, amorphous calcium carbonate (ACC). The technology was inspired by the Australian blue crayfish's ability to shed and regrow its exoskeleton in only three days. The company's ACC-based therapeutics are in clinical development for the treatment of osteoporosis, hypoparathyroidism, and a wide range of other calcium-related diseases. The technology is protected by several approved and pending patents.
Amorphical’s first product is Density, a calcium supplement based on the company’s innovative technology. Because of its molecular structure, Density is designed to be much easier for the body to absorb than most popular calcium supplements available today.
In August 2017 Amorphical signed a distribution deal with China Meheco, a state-owned pharma group, to sell the calcium supplement in China.
Amorphical currently markets and sells its product in Israel, Asia, and Latin America as a food supplement, but ACC is in trials and studies to treat diseases like hypoparathyroidism and cancer.
Amorphical is building a 3,000-square-meter (32,000-square-foot) pharmaceutical-grade facility to increase the manufacturing capacity for Density and other ACC products.
Back to this week's features.